Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Capital Expenditures (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Capital Expenditures for 6 consecutive years, with $1000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures changed N/A to $1000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $410000.0 through Dec 2025, down 79.68% year-over-year, with the annual reading at $410000.0 for FY2025, 79.68% down from the prior year.
  • Capital Expenditures for Q4 2025 was $1000.0 at Relay Therapeutics, up from -$1000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $3.4 million in Q4 2021, with the low at -$1.0 million in Q3 2021.
  • Average Capital Expenditures over 5 years is $1.0 million, with a median of $590000.0 recorded in 2023.
  • Peak annual rise in Capital Expenditures hit 5271.88% in 2021, while the deepest fall reached 167.92% in 2021.
  • Over 5 years, Capital Expenditures stood at $3.4 million in 2021, then plummeted by 32.64% to $2.3 million in 2022, then tumbled by 94.91% to $118000.0 in 2023, then skyrocketed by 92.37% to $227000.0 in 2024, then tumbled by 99.56% to $1000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $1000.0, -$1000.0, and $26000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.